Biotech · Public company · Cambridge, MA, US

Wave Life Sciences, Inc.

Ticker WVE · SEC CIK 0001631574

Track this companyFree. Adds Wave Life Sciences, Inc. to your Dealase workspace and tells you when its record changes.

Clinical trials52 recruiting or active

Pipeline programs5From trials and the company's site

Disclosed deals0None found yet

Cash runwayNot availableNo recent cash burn filed

Pipeline5

WVE-210201 (suvodirsen)Phase 3 · Duchenne Muscular DystrophyClinicalTrials.gov · fetched Nov 12, 2026
WVE-007Phase 2 · Overweight and ObesityClinicalTrials.gov · fetched Nov 12, 2026
WVE-120102Phase 2 · Huntington's DiseaseClinicalTrials.gov · fetched Nov 12, 2026
WVE-N531Phase 2 · Duchenne Muscular DystrophyClinicalTrials.gov · fetched Nov 12, 2026
WVE-210201Phase 1 · Duchenne Muscular DystrophyClinicalTrials.gov · fetched Nov 12, 2026

A Phase 1/2a Study of WVE-007 in Adults Living With Overweight or ObesityPHASE1_PHASE2 · RECRUITING · started Jan 31, 2025ClinicalTrials.gov NCT06842186 · fetched Nov 12, 2026
Open-label Study of WVE-N531 in Patients With Duchenne Muscular Dystrophy (FORWARD-53)PHASE1_PHASE2 · ACTIVE_NOT_RECRUITING · started Sep 28, 2021ClinicalTrials.gov NCT04906460 · fetched Nov 12, 2026
Efficacy and Safety Study of WVE-210201 (Suvodirsen) With Open-label Extension in Ambulatory Patients With Duchenne Muscular DystrophyPHASE2_PHASE3 · TERMINATED · started Sep 4, 2019ClinicalTrials.gov NCT03907072 · fetched Nov 12, 2026
Safety and Tolerability of WVE-210201 in Patients With Duchenne Muscular DystrophyPHASE1 · COMPLETED · started Jan 24, 2018ClinicalTrials.gov NCT03508947 · fetched Nov 12, 2026
Safety and Tolerability of WVE-120102 in Patients With Huntington's DiseasePHASE1_PHASE2 · TERMINATED · started Jul 17, 2017ClinicalTrials.gov NCT03225846 · fetched Nov 12, 2026